Streptococcus pneumoniae serotype 19A: worldwide epidemiology
R Isturiz, HL Sings, B Hilton, A Arguedas… - Expert review of …, 2017 - Taylor & Francis
Introduction: Streptococcus pneumoniae causes mucosal and invasive diseases with high
morbidity and mortality. Introduction of the 7-valent pneumococcal conjugate vaccine …
morbidity and mortality. Introduction of the 7-valent pneumococcal conjugate vaccine …
The immunological mechanisms that control pneumococcal carriage
Colonization of the human nasopharynx by pneumococcus is extremely common and is both
the primary reservoir for transmission and a prerequisite for disease. Current vaccines …
the primary reservoir for transmission and a prerequisite for disease. Current vaccines …
Waning of antibody levels induced by a 13-valent pneumococcal conjugate vaccine, using a 3+ 0 schedule, within the first year of life among children younger than 5 …
Summary Background Pneumococcal conjugate vaccines (PCVs) induce serotype-specific
IgG antibodies, effectively reducing vaccine-serotype carriage and invasive pneumococcal …
IgG antibodies, effectively reducing vaccine-serotype carriage and invasive pneumococcal …
High residual carriage of vaccine-serotype Streptococcus pneumoniae after introduction of pneumococcal conjugate vaccine in Malawi
There are concerns that pneumococcal conjugate vaccines (PCVs) in sub-Saharan Africa
sub-optimally interrupt Streptococcus pneumoniae vaccine-serotype (VT) carriage and …
sub-optimally interrupt Streptococcus pneumoniae vaccine-serotype (VT) carriage and …
Impact and effectiveness of 13-valent pneumococcal conjugate vaccine on population incidence of vaccine and non-vaccine serotype invasive pneumococcal disease …
N Bar-Zeev, TD Swarthout, DB Everett… - The Lancet Global …, 2021 - thelancet.com
Background The population impact of pneumococcal conjugate vaccines (PCVs) depends
on direct and indirect protection. Following Malawi's introduction of the 13-valent PCV …
on direct and indirect protection. Following Malawi's introduction of the 13-valent PCV …
Efficacy of a novel, protein-based pneumococcal vaccine against nasopharyngeal carriage of Streptococcus pneumoniae in infants: A phase 2, randomized, controlled …
A Odutola, MOC Ota, M Antonio, EO Ogundare… - Vaccine, 2017 - Elsevier
Background Conserved pneumococcal proteins are potential candidates for inclusion in
vaccines against pneumococcal diseases. In the first part of a two-part study, an …
vaccines against pneumococcal diseases. In the first part of a two-part study, an …
[HTML][HTML] Pneumococcal carriage in households in Karonga District, Malawi, before and after introduction of 13-valent pneumococcal conjugate vaccination
E Heinsbroek, T Tafatatha, A Phiri, TD Swarthout… - Vaccine, 2018 - Elsevier
Background Thirteen-valent pneumococcal conjugate vaccine (PCV13) was introduced in
Malawi in November 2011 and is offered to infants at 6, 10 and 14 weeks of age as part of …
Malawi in November 2011 and is offered to infants at 6, 10 and 14 weeks of age as part of …
Advances in understanding bacterial pathogenesis gained from whole-genome sequencing and phylogenetics
E Klemm, G Dougan - Cell host & microbe, 2016 - cell.com
The development of next-generation sequencing as a cost-effective technology has
facilitated the analysis of bacterial population structure at a whole-genome level and at …
facilitated the analysis of bacterial population structure at a whole-genome level and at …
[HTML][HTML] Using pneumococcal carriage studies to monitor vaccine impact in low-and middle-income countries
Pneumococcal disease is a leading cause of childhood mortality, globally. The
pneumococcal conjugate vaccine (PCV) has been introduced to many countries worldwide …
pneumococcal conjugate vaccine (PCV) has been introduced to many countries worldwide …
Persistence of nasopharyngeal pneumococcal vaccine serotypes and increase of nonvaccine serotypes among vaccinated infants and their mothers 5 years after …
E Usuf, C Bottomley, E Bojang, I Cox… - Clinical Infectious …, 2019 - academic.oup.com
Background The widespread use of pneumococcal conjugate vaccine (PCV) has brought
about a dramatic decrease in pneumococci of vaccine serotypes (VTs) but nonvaccine …
about a dramatic decrease in pneumococci of vaccine serotypes (VTs) but nonvaccine …